Page 23 - FLIPBOOK

In intermittent ADT, agonist’s reinjection for a new cycle of treatment causes

repeated T and FSH surges, linked with an increase risk of CV events in

patients.

▪ 1134 randomized to continuous vs. Adverse Health Event HR for p-

intermittent ADT on S9346 (2) continuous ADT

▪ 636 (56%) of trial participants had Ischemic and Thrombotic Events 0.48 .02

≥1 year of continuous Medicare

parts A&B coverage and no HMO Acute MI 0.57 .22

participation.
Ischemic Heart Disease 0.35 .04

Thrombosis (severe) 0.79 .57

Hershman DL et al. JAMA Oncol. 2016 2(4):453-61.